JP6019118B2 - 吸入に適した酸化型アビジンの医薬品組成物 - Google Patents
吸入に適した酸化型アビジンの医薬品組成物 Download PDFInfo
- Publication number
- JP6019118B2 JP6019118B2 JP2014523289A JP2014523289A JP6019118B2 JP 6019118 B2 JP6019118 B2 JP 6019118B2 JP 2014523289 A JP2014523289 A JP 2014523289A JP 2014523289 A JP2014523289 A JP 2014523289A JP 6019118 B2 JP6019118 B2 JP 6019118B2
- Authority
- JP
- Japan
- Prior art keywords
- biotinylated
- group
- pharmaceutical composition
- inhalation
- oxidized avidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11006338 | 2011-08-02 | ||
| EP11006338.5 | 2011-08-02 | ||
| PCT/EP2012/064576 WO2013017494A1 (en) | 2011-08-02 | 2012-07-25 | Pharmaceutical composition of oxidised avidin suitable for inhalation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014521675A JP2014521675A (ja) | 2014-08-28 |
| JP2014521675A5 JP2014521675A5 (cg-RX-API-DMAC7.html) | 2015-08-27 |
| JP6019118B2 true JP6019118B2 (ja) | 2016-11-02 |
Family
ID=46581966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014523289A Active JP6019118B2 (ja) | 2011-08-02 | 2012-07-25 | 吸入に適した酸化型アビジンの医薬品組成物 |
Country Status (19)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2941243A4 (en) | 2013-01-04 | 2016-09-14 | Massachusetts Inst Technology | SURFACE BINDING IN THE ADMINISTRATION OF A MEDICAMENT ON NANOPARTICLE BASE IN A TISSUE |
| EP3458097A4 (en) * | 2016-05-19 | 2020-01-08 | University of Miami | TARGETED DELIVERY OF THERAPEUTIC AGENTS AND IMAGING REAGENTS TO CANCER PANCREAS CELLS |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5384128A (en) * | 1993-03-02 | 1995-01-24 | University Of Alabama Research Foundation | Method of and compounds for treatment for cystic fibrosis |
| WO1995003034A1 (en) | 1993-07-19 | 1995-02-02 | Amgen Inc. | Stabilization of aerosolized proteins |
| DE69830305T2 (de) * | 1997-02-20 | 2006-02-02 | Dime, David S., Toronto | Ortsspezifische arzneimittel verabreichung |
| EP1169053A1 (en) * | 1999-04-13 | 2002-01-09 | Inhale Therapeutic Systems, Inc. | Pulmonary administration of dry powder formulations for treating infertility |
| US7001994B2 (en) * | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| ITRM20010079A1 (it) | 2001-02-16 | 2002-08-16 | Sigma Tau Ind Farmaceuti | Amminoderivati della biotina e loro coniugati con chelanti macrociclici. |
| ITRM20030196A1 (it) * | 2003-04-24 | 2004-10-25 | Sigma Tau Ind Farmaceuti | Uso di reagenti per la preparazione di un medicamento |
| BRPI0517204A (pt) * | 2004-12-17 | 2008-09-30 | Cipla Ltd | sulfato de levosalbutamol cristalino (forma i), sulfato de levosalbutamol cristalino (forma ii), sulfato de levosalbutamol cristalino (forma iii), processo para preparar a forma i do sulfato de levosalbutamol cristalino, processo para preparar a forma ii do sulfato de levosalbutamol cristalino, processo para preparar a forma iii do sulfato de levosalbutamol, composição farmacêutica, composto, combinação, pó seco para inalador, processo para preparar um pó seco para inalador, processo para preparar uma composição famacêutica, processo para fabricação de uma composição farmacêutica, método para tratamento de um mamìfero, e uso de uma combinação de salbutamol |
| GB0602778D0 (en) * | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
| US8562947B2 (en) * | 2007-08-02 | 2013-10-22 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Oxidized avidin with high residency time in the treated tissues |
| EP2106806A1 (en) | 2008-03-31 | 2009-10-07 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Nanoparticles for targeted delivery of active agents to the lung |
| TW201031436A (en) * | 2009-02-16 | 2010-09-01 | Univ Nat Taiwan | Pharmaceutical composition for inhalation delivery and fabrication method thereof |
-
2012
- 2012-07-25 EA EA201490401A patent/EA026453B1/ru not_active IP Right Cessation
- 2012-07-25 PH PH1/2014/500193A patent/PH12014500193A1/en unknown
- 2012-07-25 KR KR1020147001707A patent/KR101966630B1/ko active Active
- 2012-07-25 JP JP2014523289A patent/JP6019118B2/ja active Active
- 2012-07-25 DK DK12740137.0T patent/DK2739314T3/da active
- 2012-07-25 ES ES12740137T patent/ES2729549T3/es active Active
- 2012-07-25 CN CN201280037217.9A patent/CN103717239B/zh active Active
- 2012-07-25 MX MX2014001176A patent/MX355177B/es active IP Right Grant
- 2012-07-25 BR BR112014002593-2A patent/BR112014002593B1/pt not_active IP Right Cessation
- 2012-07-25 CA CA2842276A patent/CA2842276C/en active Active
- 2012-07-25 EP EP12740137.0A patent/EP2739314B1/en active Active
- 2012-07-25 PL PL12740137T patent/PL2739314T3/pl unknown
- 2012-07-25 WO PCT/EP2012/064576 patent/WO2013017494A1/en not_active Ceased
- 2012-07-25 PT PT12740137T patent/PT2739314T/pt unknown
- 2012-07-25 UA UAA201402021A patent/UA114482C2/uk unknown
- 2012-07-25 AU AU2012292229A patent/AU2012292229B2/en active Active
- 2012-07-25 US US14/236,445 patent/US9872831B2/en active Active
-
2014
- 2014-01-22 IL IL230597A patent/IL230597A0/en active IP Right Grant
- 2014-02-27 ZA ZA2014/01921A patent/ZA201401921B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012292229A1 (en) | 2014-02-13 |
| EP2739314B1 (en) | 2019-05-22 |
| WO2013017494A1 (en) | 2013-02-07 |
| PL2739314T3 (pl) | 2019-09-30 |
| UA114482C2 (uk) | 2017-06-26 |
| CA2842276A1 (en) | 2013-02-07 |
| CA2842276C (en) | 2020-11-24 |
| KR20140047668A (ko) | 2014-04-22 |
| MX2014001176A (es) | 2014-07-14 |
| US9872831B2 (en) | 2018-01-23 |
| EA201490401A1 (ru) | 2014-05-30 |
| AU2012292229B2 (en) | 2017-08-03 |
| DK2739314T3 (da) | 2019-06-24 |
| IL230597A0 (en) | 2014-03-31 |
| MX355177B (es) | 2018-04-09 |
| JP2014521675A (ja) | 2014-08-28 |
| PT2739314T (pt) | 2019-06-21 |
| BR112014002593A2 (pt) | 2017-03-01 |
| KR101966630B1 (ko) | 2019-04-09 |
| ES2729549T3 (es) | 2019-11-04 |
| ZA201401921B (en) | 2015-05-27 |
| BR112014002593B1 (pt) | 2022-11-29 |
| CN103717239B (zh) | 2017-08-01 |
| US20140134106A1 (en) | 2014-05-15 |
| CN103717239A (zh) | 2014-04-09 |
| EA026453B1 (ru) | 2017-04-28 |
| PH12014500193A1 (en) | 2014-03-24 |
| NZ620202A (en) | 2016-05-27 |
| EP2739314A1 (en) | 2014-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation | |
| US11684584B2 (en) | Branched peg molecules and related compositions and methods | |
| US9616137B2 (en) | Nanoparticle-based tumor-targeted drug delivery | |
| Maillet et al. | The airways, a novel route for delivering monoclonal antibodies to treat lung tumors | |
| EP2185203B1 (en) | Oxidized avidin with high residency time in the treated tissues | |
| JP2007501239A (ja) | 放射線治療と組み合わせたｖｅｇｆアンタゴニストの使用 | |
| JP6019118B2 (ja) | 吸入に適した酸化型アビジンの医薬品組成物 | |
| CN116675779B (zh) | 一种靶向Src激酶的短肽及其在系统性真菌感染中的应用 | |
| JP2002540172A (ja) | 腫瘍治療の増強のためのスフィンゴミエリン含有調製物 | |
| HK1194002B (en) | Pharmaceutical composition of oxidised avidin suitable for inhalation | |
| NZ620202B2 (en) | Pharmaceutical composition of oxidised avidin suitable for inhalation | |
| HK1194002A (en) | Pharmaceutical composition of oxidised avidin suitable for inhalation | |
| US20230381349A1 (en) | Methods and compositions for imaging and treating cancer | |
| US20230285572A1 (en) | Targeted delivery of therapeutic agents | |
| EP4373522A1 (en) | Engineered compositions for bone-targeted therapy | |
| TWI851090B (zh) | 雙股寡去氧核苷酸、包含該雙股寡去氧核苷酸的組合物及其用途 | |
| WO2025188920A1 (en) | Local application of agents inhibiting tyrosine kinase or shp-1 signaling | |
| US6331528B1 (en) | Method for treatment in gene therapy and use of guanine derivative therefor | |
| Huayamares et al. | Current Research in Biotechnology | |
| JP4395901B2 (ja) | 新規遺伝子治療用薬剤 | |
| WO2025041055A1 (en) | Anti-psma adc conjugate compositions and methods of use thereof | |
| Dhand | Lung cancer inhalation therapeutics | |
| TW202535478A (zh) | 抗ｂ７ｈ３抗體－藥物偶聯物治療癌症的方法 | |
| CN115279393A (zh) | 以介白素24或介白素20拮抗剂治疗组织纤维化和/或损伤和/或器官衰竭 | |
| WO2020232638A1 (zh) | 一种抗体偶联物及其药物组合物的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150708 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150708 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160425 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160721 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160905 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161003 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6019118 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |